Ali, Haris
Mayo Clinic
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
Citations 2
A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
Tamari, Roni , McLornan, Donal P. , Ahn, Kwang Woo , Estrada‐Merly, Noel, Hernández‐Boluda, Juan Carlos , Giralt, Sergio , Palmer, Jeanne , DeFilipp, Zachariah , Marks, David I. , Poel, Marjolein van der , Verdonck, Leo F. , Gupta, Vikas , Ali, Haris , Litzow, Mark R. , Bashey, Asad, Hashmi, Shahrukh K. , Bredeson, Christopher , Rizzieri, David A. , Abid, Muhammad Bilal , Ganguly, Siddhartha , Wirk, Baldeep , Aljurf, Mahmoud , Kindwall‐Keller, Tamila L. , Kharfan‐Dabaja, Mohamed A. , Hildebrandt, Gerhard , Pawarode, Attaphol , Solh, Melhem , Nathan, Sunita , Seo, Sachiko , Scott, Bart L. , Nakamura, Ryotaro , Yakoub‐Agha, Ibrahim , Saber, Wael , DeFilipp, Zachariah , Gupta, Vikas , Ali, Haris , Litzow, Mark R. , Hashmi, Shahrukh K , Pu, Jeffrey J , Bacher, Ulrike , Jain, Tania , Cutler, Corey S. , Kharfan-Dabaja, Mohamed A , Yared, Jean A , Nishihori, Taiga , Seo, Sachiko , Scott, Bart , Nakamura, Ryotaro , Czerw, Tomasz , Yakoub-Agha, Ibrahim , Hernández-Boluda, Juan Carlos , McLornan, Donal , Abid, Muhammad Bilal , Giralt, Sergio , Gale, Robert Peter , Battiwalla, Minoo , Díaz, Miguel Ángel , Lazarus, Hillard M. , Gergis, Usama , Liesveld, Jane L. , Beitinjaneh, Amer , Savani, Bipin N. , Agrawal, Vaibhav , Jain, Tania , Yared, Jean A. , Grunwald, Michael R. , Nishihori, Taiga , Oran, Betül
Blood Advances | May 3, 2023 | Volume: 7 | Issue: 15 | Pages: 3993-4002
10.1182/bloodadvances.2023009886
AbstractTo develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in the United States (the Center for International Blood and Marrow Transplant Research [CIBMTR] cohort). A Cox multivariable model was used to identify factors prognostic of mortality. A weighted score using these factors was assigned to patients who received transplantation in Europe (the European Bone Marrow Transplant [EBMT] cohort; n = 623). Patient age >50 years (hazard ratio [HR], 1.39; 95% confidence interval [CI], 0.98-1.96), and HLA-matched unrelated donor (HR, 1.29; 95% CI, 0.98-1.7) were associated with an increased hazard of death and were assigned 1 point. Hemoglobin levels <100 g/L at time of transplantation (HR, 1.63; 95% CI, 1.2-2.19) and a mismatched unrelated donor (HR, 1.78; 95% CI, 1.25-2.52) were assigned 2 points. The 3-year overall survival (OS) in patients with a low (1-2 points), intermediate (3-4 points), and high score (5 points) were 69% (95% CI, 61-76), 51% (95% CI, 46-56.4), and 34% (95% CI, 21-49), respectively (P < .001). Increasing score was predictive of increased transplant-related mortality (TRM; P = .0017) but not of relapse (P = .12). The derived score was predictive of OS (P < .001) and TRM (P = .002) but not of relapse (P = .17) in the EBMT cohort as well. The proposed system was prognostic of survival in 2 large cohorts, CIBMTR and EBMT, and can easily be applied by clinicians consulting patients with MF about the transplantation outcomes.
Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration
Jain, Tania , Tsai, Hua‐Ling , Elmariah, Hany , Vachhani, Pankit , Wall, Sarah , Gondek, Lukasz P. , Bashey, Asad, Keyzner, Alla , Tamari, Roni , Nadiminti, Kalyan , Ali, Haris , Jones, Richard J. , Gondek, Lukasz , Tamari, Roni , Grunwald, Michael , Gerds, Aaron T , McCurdy, Shannon , Al Malki, Monzr M , Ali, Haris , Gupta, Vikas , Jain, Tania , Elmariah, Hany , Karantanos, Theodoros , Grunwald, Michael R. , Abedin, Sameem , Iqbal, Madiha , Gerds, Aaron T. , Viswabandya, Auro , Malki, Monzr M. Al , Varadhan, Ravi , Gupta, Vikas , Otoukesh, Salman
No container title available | March 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available
AbstractHaploidentical donors offer a potentially readily available donor, especially for non-White patients, for blood or marrow transplantation (BMT). In this collaboration across North America, we retrospectively analyzed outcomes of first BMT using haploidentical donor and posttransplantation cyclophosphamide (PTCy) in MDS/MPN-overlap neoplasms (MDS/MPN), an otherwise incurable hematological neoplasm. We included 120 patients, 38% of non-White/Caucasian ethnicity, across 15 centers with median age at BMT 62.5 years. The median follow-up is 2.4 years. Graft failure was reported in 6% patients. At 3-years, nonrelapse mortality (NRM) was 25%, relapse 27%, grade 3-4 acute graft versus host disease (GVHD) 12%, chronic GVHD requiring systemic immunosuppression 14%, progression-free survival (PFS) 48% and overall survival (OS) 56%. On multivariable analysis, statistically significant associations included older age at BMT (per decade increment) with NRM (sdHR 3.28, 95%CI 1.30-8.25), PFS (HR 1.98, 95% 1.13-3.45) and OS (HR 2.01, 95% CI 1.11-3.63), presence of mutation in EZH2/RUNX1/SETBP1 with relapse (sdHR 2.61, 95%CI 1.06-6.44), and splenomegaly at BMT/prior splenectomy with OS (HR 2.20, 95%CI 1.04-4.65). Haploidentical donors are a viable option for BMT in MDS/MPN, especially for those disproportionately represented in the unrelated donor registry. Disease-related factors including splenomegaly and high-risk mutations dominate outcomes following BMT.